Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring provides an overview of past and present gene therapy development, plus the progress of clinical trials and key challenges in the sector.
Gene therapy is an innovative, fast-evolving modality offering revolutionary capability in multiple disease areas. According to research by 360iresearch, the global cell & gene therapy market is estimated to value $135.04 billion by 2030.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
In this Q&A, Karen Pinachyan, Head of Medical Affairs Europe at CSL Behring summarises key considerations for gene therapy drug development and the ideal approach for alleviating economic strain when advancing these modern treatments.
How has the gene therapy landscape evolved over the last several years?
The clinical application of gene therapy has been investigated for decades, with the first clinical trial of such a treatment for a rare inherited form of immunodeficiency taking place in the US in 1990.1 It took another 22 years for the first drug to be approved in North America or Europe, when the European Medicines Agency (EMA) granted conditional approval for an adeno-associated virus (AAV) drug indicated for the treatment of a rare lipid disorder, lipoprotein lipase deficiency.2
Since then, the pace of research and development has increased considerably, to the point where there are now more than 2,500 active clinical trials taking place.3 Gene therapies have evolved and new approaches have led to greater precision in making changes in the genome. For example, AAV based gene therapy delivers the functional gene in a single dose to treat genetic disorders.
Considerable progress has been made in other areas including enhancing safety, improving treatment administration and patient monitoring systems and implementing innovative pricing strategies – all with the goal of providing timely access to eligible patients who can benefit from these treatments.
What is the main reason economic uncertainties are impacting the gene therapy sector? How could this be mitigated?
As gene therapies are highly innovative, with many new treatments being the first of their kind, substantial investments are required across multiple stages, including extensive research, clinical trials and specialised manufacturing processes. Economic uncertainties can therefore lie in the high cost involved in drug development, manufacturing and delivery.
The impact of a one-time gene therapy treatment on national health budgets must also be considered, particularly at a time when many healthcare systems are facing financial challenges. Mitigating these economic concerns requires a multi-faceted approach, including appropriate models to assess and account for the projected long-term durability and potential cost savings for gene therapies. Fair and value-based pricing models, collaborative partnerships, and investment incentives can help align the cost of gene therapies with their clinical, societal and economic benefits.
What is the biggest impact gene therapy is having on clinical trials?
As more investigational gene therapies reach the clinical trial stage, including those focused on rare genetic diseases that were previously considered too challenging to treat, we are seeing the emergence of novel trial designs.
Particularly, haemophilia is often seen as a case study for gene therapy in the rare disease space. This modality has the potential to provide these patients with freedom from bleeds and the burden of lifelong treatment.
As more investigational gene therapies reach clinical trials, including those focused on rare genetic diseases that were previously considered too challenging to treat, we are seeing the emergence of novel trial designs.
The small numbers of people diagnosed with rare genetic diseases, as well as the overall health of the patients means that we have had to rethink the trial process from end to end.
But it is not only the pre-approval trials that have seen changes – this therapy has also shifted the wider relationship between industry, patients and health care professionals. For example, market access authorisation comes with a requirement to monitor patients for much longer than traditional medicines. In Europe, the EMA requires up to a 15-year follow up of patients. The US Food and Drug Administration (FDA) requires a patient follow up period of at least 10-15 years.4,5
What is the key consideration drug developers should apply to gene therapies?
Gene therapies have the potential to transform the lives of people with genetic diseases. However, essential considerations for gene therapies include early drug development and evidence planning. For example, this involves identification of the patient population, disease subtypes, competitor analysis, and evidence of an unmet need.
Developing a novel therapy can be very expensive due to the complexities of and investment required in R&D, as well as manufacturing costs. This is amplified by the fact that gene therapies are often developed to treat rare diseases, so the number of patients to be treated is limited. Pharmaceutical companies need to work closely with governments and health authorities to find innovative contracting and payment models, such as outcome-based agreements, which consider the clinical and economic value of the treatment to patients, healthcare systems and society.
It is also important for pharmaceutical companies to work closely with specialists and clinical treatment centres to ensure they are prepared to identify eligible patients, administer gene therapies and monitor patients in the long-term. This close collaboration is vital to ensuring the future delivery of care.
About the interviewee
Karen Pinachyan is the Head of Medical Affairs Europe at CSL Behring and works with his team across five therapeutic areas; immunology, haematology (including gene therapy), respiratory, cardio-metabolism and transplant.
A physician specialised in otolaryngology and head and neck surgery by training, Since starting his pharmaceutical industry journey in 2006, he has acquired extensive medical affairs and clinical development experience across various therapeutic areas, both in rare diseases and more prevalent conditions, such as diabetes and heart failure.
References
Blaese RM, Culver KW, Miller AD, et al. Science. 1995; 270(5235): 475-480.
Long Term Follow-Up After Administration of Human Gene Therapy Product. [Internet] FDA. 2020. [cited 2023August]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/long-term-follow-after-administration-human-gene-therapy-products.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.